Stay updated on Radiation and Checkpoints in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Radiation and Checkpoints in NSCLC Clinical Trial page.

Latest updates to the Radiation and Checkpoints in NSCLC Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check22 days agoChange DetectedThe page has been updated to reflect a new treatment protocol for Non-Small Cell Lung Cancer (NSCLC) patients, including specific dosages and timing for ipilimumab and nivolumab, as well as changes in eligibility criteria and study details. The principal investigator's name and affiliation have also been added.SummaryDifference42%
- Check30 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check73 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check88 days agoChange DetectedThe web page now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference1%
- Check95 days agoChange DetectedThe website has been updated from version 2.14.1 to 2.14.2.SummaryDifference0.1%
Stay in the know with updates to Radiation and Checkpoints in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Radiation and Checkpoints in NSCLC Clinical Trial page.